Sam Chun Dang Pharm Faces Funding Concerns Amid 200 Billion Won Corporate Tax Assessment

Sam Chun Dang Pharm is facing projections of potential funding difficulties after being notified that it must pay an additional corporate tax of approximately 200 billion won. This has led to concerns about the company's financial health. In December 2023, Sam Chun Dang Pharm was assessed a surcharge of around 200 billion won for its 2022 corporate taxes.

This surcharge exceeds the company's annual operating profit for last year (114.4 billion won). Sam Chun Dang Pharm's stock price plummeted after suspicions related to this tax issue emerged, and its market capitalization has decreased by about half, roughly 8 trillion won, in the last three trading days, suffering a blow in the capital market.

Sam Chun Dang Pharm has yet to issue an official statement regarding the tax assessment, and market concerns surrounding the matter persist.